158 related articles for article (PubMed ID: 28978117)
1. A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
D'Arrigo P; Russo M; Rea A; Tufano M; Guadagno E; Del Basso De Caro ML; Pacelli R; Hausch F; Staibano S; Ilardi G; Parisi S; Romano MF; Romano S
Oncotarget; 2017 Sep; 8(40):68291-68304. PubMed ID: 28978117
[TBL] [Abstract][Full Text] [Related]
2. The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation.
D'Arrigo P; Digregorio M; Romano S; Tufano M; Rea A; Hausch F; Dedobbeleer M; Vigorito V; Russo S; Bauder M; Rogister B; Romano MF
Cell Death Discov; 2019; 5():137. PubMed ID: 31583120
[TBL] [Abstract][Full Text] [Related]
3. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.
Tufano M; D'Arrigo P; D'Agostino M; Giordano C; Marrone L; Cesaro E; Romano MF; Romano S
Cells; 2021 Sep; 10(9):. PubMed ID: 34572014
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients.
Romano S; D'Angelillo A; Staibano S; Simeone E; D'Arrigo P; Ascierto PA; Scalvenzi M; Mascolo M; Ilardi G; Merolla F; Jovarauskaite E; Romano MF
Pigment Cell Melanoma Res; 2015 Jul; 28(4):442-52. PubMed ID: 25895097
[TBL] [Abstract][Full Text] [Related]
6. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma.
Giordano C; Marrone L; Romano S; Della Pepa GM; Donzelli CM; Tufano M; Capasso M; Lasorsa VA; Quintavalle C; Guerri G; Martucci M; Auricchio A; Gessi M; Sala E; Olivi A; Romano MF; Gaudino S
Cancer Res Commun; 2024 May; 4(5):1296-1306. PubMed ID: 38651817
[TBL] [Abstract][Full Text] [Related]
7. Combining Magnetic Resonance Imaging with Systemic Monocyte Evaluation for the Implementation of GBM Management.
Giordano C; Sabatino G; Romano S; Della Pepa GM; Tufano M; D'Alessandris QG; Cottonaro S; Gessi M; Balducci M; Romano MF; Olivi A; Gaudino S; Colosimo C
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33917598
[TBL] [Abstract][Full Text] [Related]
8. Alternative splicing of FKBP5 gene exerts control over T lymphocyte expansion.
Marrone L; D'Agostino M; Cesaro E; di Giacomo V; Urzini S; Romano MF; Romano S
J Cell Biochem; 2023 Jan; ():. PubMed ID: 36645880
[TBL] [Abstract][Full Text] [Related]
9. FKBP51s signature in peripheral blood mononuclear cells of melanoma patients as a possible predictive factor for immunotherapy.
Romano S; Simeone E; D'Angelillo A; D'Arrigo P; Russo M; Capasso M; Lasorsa VA; Zambrano N; Ascierto PA; Romano MF
Cancer Immunol Immunother; 2017 Sep; 66(9):1143-1151. PubMed ID: 28434031
[TBL] [Abstract][Full Text] [Related]
10. Function of PD-L1 in antitumor immunity of glioma cells.
Lou Y; Shi J; Guo D; Qureshi AK; Song L
Saudi J Biol Sci; 2017 May; 24(4):803-807. PubMed ID: 28490949
[TBL] [Abstract][Full Text] [Related]
11. Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo.
Blomberg E; Silginer M; Roth P; Weller M
Neurooncol Adv; 2022; 4(1):vdac148. PubMed ID: 36212740
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration.
Zhang L; Zhang Z; Liu Y; Xue Y; Parney I
Med Hypotheses; 2015 Aug; 85(2):127-9. PubMed ID: 25936667
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.
Derer A; Spiljar M; Bäumler M; Hecht M; Fietkau R; Frey B; Gaipl US
Front Immunol; 2016; 7():610. PubMed ID: 28066420
[TBL] [Abstract][Full Text] [Related]
14. PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Cao J; Brouwer NJ; Richards KE; Marinkovic M; van Duinen S; Hurkmans D; Verdegaal EME; Jordanova ES; Jager MJ
Oncotarget; 2017 Aug; 8(33):54722-54734. PubMed ID: 28903377
[TBL] [Abstract][Full Text] [Related]
15. Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma.
Peng H; Li Z; Fu J; Zhou R
Cancer Manag Res; 2019; 11():2653-2661. PubMed ID: 31114328
[No Abstract] [Full Text] [Related]
16. Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model.
Yamaguchi I; Nakajima K; Shono K; Mizobuchi Y; Fujihara T; Shikata E; Yamaguchi T; Kitazato K; Sampetrean O; Saya H; Takagi Y
Neurooncol Adv; 2020; 2(1):vdz058. PubMed ID: 32642723
[TBL] [Abstract][Full Text] [Related]
17. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX
Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840
[TBL] [Abstract][Full Text] [Related]
18. Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Vera-Aguilera J; Perez-Torres A; Beltran D; Villanueva-Ramos C; Wachtel M; Moreno-Aguilera E; Vera-Aguilera C; Ventolini G; Martínez-Zaguilán R; Sennoune SR
Cancer Biother Radiopharm; 2017 Mar; 32(2):49-56. PubMed ID: 28301259
[TBL] [Abstract][Full Text] [Related]
19. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Blank C; Kuball J; Voelkl S; Wiendl H; Becker B; Walter B; Majdic O; Gajewski TF; Theobald M; Andreesen R; Mackensen A
Int J Cancer; 2006 Jul; 119(2):317-27. PubMed ID: 16482562
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.
Baban B; Liu JY; Qin X; Weintraub NL; Mozaffari MS
PLoS One; 2015; 10(4):e0124059. PubMed ID: 25902191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
